Cai Liu, Du Yanyuan, Xiong Hongtai, Zheng Honggang
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2024 Nov 29;15:1438819. doi: 10.3389/fphar.2024.1438819. eCollection 2024.
Hepatocellular carcinoma is the predominant histologic variant of hepatic malignancy and has become a major challenge to global health. The increasing incidence and mortality of hepatocellular carcinoma has created an urgent need for effective prevention, diagnosis, and treatment strategies. This is despite the impressive results of multiple treatments in the clinic. However, the unique tumor immunosuppressive microenvironment of hepatocellular carcinoma increases the difficulty of treatment and immune tolerance. In recent years, the application of nanoparticles in the treatment of hepatocellular carcinoma has brought new hope for tumor patients. Nano agents target tumor-associated fibroblasts, regulatory T cells, myeloid suppressor cells, tumor-associated macrophages, tumor-associated neutrophils, and immature dendritic cells, reversed the immunosuppressive microenvironment of hepatocellular carcinoma. In addition, he purpose of this review is to summarize the advantages of nanotechnology in guiding surgical excision, local ablation, TACE, standard chemotherapy, and immunotherapy, application of nano-vaccines has also continuously enriched the treatment of liver cancer. This study aims to investigate the potential applications of nanotechnology in the management of hepatocellular carcinoma, with the ultimate goal of enhancing therapeutic outcomes and improving the prognosis for patients affected by this malignancy.
肝细胞癌是肝脏恶性肿瘤的主要组织学类型,已成为全球健康的一大挑战。肝细胞癌发病率和死亡率的不断上升,迫切需要有效的预防、诊断和治疗策略。尽管临床上多种治疗方法取得了令人瞩目的成果,但肝细胞癌独特的肿瘤免疫抑制微环境增加了治疗难度和免疫耐受性。近年来,纳米颗粒在肝细胞癌治疗中的应用为肿瘤患者带来了新希望。纳米制剂靶向肿瘤相关成纤维细胞、调节性T细胞、髓源性抑制细胞、肿瘤相关巨噬细胞、肿瘤相关中性粒细胞和未成熟树突状细胞,逆转了肝细胞癌的免疫抑制微环境。此外,本综述的目的是总结纳米技术在指导手术切除、局部消融、经动脉化疗栓塞、标准化疗和免疫治疗方面的优势,纳米疫苗的应用也不断丰富了肝癌的治疗手段。本研究旨在探讨纳米技术在肝细胞癌治疗中的潜在应用,最终目标是提高治疗效果,改善受这种恶性肿瘤影响患者的预后。